Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.57 |
| ▸ | ACE | P12821 | 5/20 | 0.57 |
| ▸ | CPA1 | P15085 | 2/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | IL2 | P60568 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | FCER2 | P06734 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779293 | 0.85 | PPARG (0.53) | MMEACECPA1ACE2PPARG | |
| SCHEMBL2779289 | 0.85 | PPARG (0.53) | MMEACECPA1ACE2PPARG | |
| SCHEMBL24625336 | 0.83 | MME (0.59) | MMEACECPA1ACE2CA2 | |
| SCHEMBL18435353 | 0.83 | MME (0.59) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29377272 | 0.83 | MME (0.59) | MMEACECPA1ACE2CA2 | |
| SCHEMBL10071066 | 0.83 | MME (0.61) | MMEACECPA1ACE2CA2 | |
| SCHEMBL8895051 | 0.83 | MME (0.61) | MMEACECPA1ACE2CA2 | |
| SCHEMBL805215 | 0.83 | MME (0.61) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29697199 | 0.83 | MME (0.59) | MMEACECPA1ACE2CA2 | |
| SCHEMBL30498632 | 0.83 | MME (0.61) | MMEACECPA1ACE2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | MME 316/4885ACE 2124/4885CPA1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.